Quantcast
Home > Quotes > AVRO

AVROBIO, Inc. Common Stock (AVRO) Quote & Summary Data

AVRO 
$14.87
*  
0.22
1.5%
Get AVRO Alerts
*Delayed - data as of Mar. 27, 2020  -  Find a broker to begin trading AVRO now
Exchange:NASDAQ
Industry: Health Care
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
35
Today's High / Low
$ 15.9999 / $ 14.07
Share Volume
258,061
50 Day Avg. Daily Volume
383,362
Previous Close
$ 14.65
52 Week High / Low
$ 29.32 / $ 9.76
Market Cap
535,773,461
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2.68
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1

Intraday Chart

Shares Traded

Share Volume:
258,061
50 Day Avg. Daily Volume:
383,362

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2.68

Trading Range

The current last sale of $14.87 is 52.36% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 15.9999 $ 29.32
 Low: $ 14.07 $ 9.76

Company Description (as filed with the SEC)

We are a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease. Our company is focused on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. Our gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is defective in the target disease. We believe that our approach, which is designed to transform stem cells from patients into therapeutic products, has the potential to provide curative benefit for a range of diseases. Our initial focus is on a group of rare genetic diseases referred to as lysosomal diseases, some of which today are primarily managed with enzyme replacement therapies, or ERTs.  ... More ...  



Risk Grade

Where does AVRO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 14.07
Open Date:
Mar. 27, 2020
Close Price:
$ 14.87
Close Date:
Mar. 27, 2020


Consensus Recommendation

Analyst Info